Premium
Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[ 18 F]‐D‐glucose
Author(s) -
Oshida Masaki,
Uno Kimiichi,
Suzuki Masato,
Nagashima Takeshi,
Hashimoto Hideyuki,
Yagata Hiroshi,
Shishikura Tanetomo,
Imazeki Keiko,
Nakajima Nobuyuki
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980601)82:11<2227::aid-cncr18>3.0.co;2-w
Subject(s) - medicine , breast cancer , positron emission tomography , proportional hazards model , breast carcinoma , carcinoma , nuclear medicine , standardized uptake value , log rank test , oncology , multivariate analysis , survival analysis , cancer
Abstract BACKGROUND Positron emission tomography (PET) with 2‐deoxy‐2‐fluoro[ 18 F]‐D‐glucose (FDG) can provide quantitative information about tumor glucose metabolism. The prognostic value of this technique was evaluated for breast carcinoma patients. METHODS FDG PET was performed on 70 patients with primary breast carcinoma, and the differential absorption ratio (DAR) was calculated as an index of FDG uptake. Overall and relapse free survival curves were created by the Kaplan‐Meier method, and differences between the curves were analyzed with the log rank test. For multivariate analysis, the Cox proportional hazards regression model was used. RESULTS The mean DAR was 2.61 ± 1.61 standard deviation (range, 0.65‐9.39). According to the grade of DAR, patients were then classified into high DAR (≥3.0) and low DAR (<3.0) groups. The high DAR group had significantly worse prognoses for both overall and relapse free survival ( P < 0.0005 and P < 0.0001, respectively). In multivariate analysis, DAR was an independent predictor of the relapse free survival of breast carcinoma patients ( P = 0.0377). CONCLUSIONS DAR, as determined by FDG PET, may be useful as a prognostic indicator for patients with primary breast carcinoma. Cancer 1998;82:2227‐2234. © 1998 American Cancer Society.